The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

A K Burnett, R K Hills, A E Hunter, D Milligan, W J Kell, K Wheatley, J Yin, M F McMullin, H Dignum, D Bowen, N H Russell, UK National Cancer Research Institute AML Working Group

Research output: Contribution to journalArticle

113 Citations (Scopus)

Fingerprint Dive into the research topics of 'The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison'. Together they form a unique fingerprint.

Medicine & Life Sciences